These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8365089)

  • 1. Action profile of the rapid acting insulin analogue: human insulin B28Asp.
    Heinemann L; Heise T; Jorgensen LN; Starke AA
    Diabet Med; 1993 Jul; 10(6):535-9. PubMed ID: 8365089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Action profiles of fast onset insulin analogues.
    Heinemann L; Starke AA; Heding L; Jensen I; Berger M
    Diabetologia; 1990 Jun; 33(6):384-6. PubMed ID: 2199281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulinkinetic and -dynamic in diabetic patients under insulin pump therapy after injections of human insulin or the insulin analogue (B28Asp).
    Wiefels K; Hübinger A; Dannehl K; Gries FA
    Horm Metab Res; 1995 Sep; 27(9):421-4. PubMed ID: 8557242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.
    Weyer C; Heise T; Heinemann L
    Diabetes Care; 1997 Oct; 20(10):1612-4. PubMed ID: 9314644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
    Heinemann L; Weyer C; Rave K; Stiefelhagen O; Rauhaus M; Heise T
    Exp Clin Endocrinol Diabetes; 1997; 105(3):140-4. PubMed ID: 9228509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10, AspB28) in healthy subjects.
    Kang S; Brange J; Burch A; Vølund A; Owens DR
    Diabetes Care; 1991 Nov; 14(11):1057-65. PubMed ID: 1797487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
    Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T
    Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel insulin formulation with a more rapid onset of action.
    Steiner S; Hompesch M; Pohl R; Simms P; Flacke F; Mohr T; Pfützner A; Heinemann L
    Diabetologia; 2008 Sep; 51(9):1602-6. PubMed ID: 18641968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
    Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
    Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
    Jacobs MA; Salobir B; Popp-Snijders C; Ader H; Heine RJ
    Diabet Med; 1997 Mar; 14(3):248-57. PubMed ID: 9088775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin.
    Heinemann L; Chantelau EA; Starke AA
    Diabete Metab; 1992; 18(1):21-4. PubMed ID: 1563532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the pharmacodynamic profiles of jet-injected regular human insulin versus conventionally administered insulin aspart in healthy volunteers.
    Engwerda EEC; Tack CJ; de Galan BE
    Diabetes Res Clin Pract; 2016 Nov; 121():86-90. PubMed ID: 27662042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects.
    Vora JP; Owens DR; Dolben J; Atiea JA; Dean JD; Kang S; Burch A; Brange J
    BMJ; 1988 Nov; 297(6658):1236-9. PubMed ID: 3145064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.
    Arnolds S; Rave K; Hövelmann U; Fischer A; Sert-Langeron C; Heise T
    Exp Clin Endocrinol Diabetes; 2010 Oct; 118(9):662-4. PubMed ID: 20429049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304.
    Heinemann L; Sinha K; Weyer C; Loftager M; Hirschberger S; Heise T
    Diabet Med; 1999 Apr; 16(4):332-8. PubMed ID: 10220208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.